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By Arthur Robin Williams, Mark Olfson, June H. Kim, Silvia S. Martins, and Herbert D. Kleber
Older, Less Regulated Medical
Marijuana Programs Have Much
Greater Enrollment Rates Than
Newer ‘Medicalized’ Programs
ABSTRACT Twenty-three states and the District of Columbia have passed
laws implementing medical marijuana programs. The nineteen programs
that were in operation as of October 2014 collectively had over one
million participants. All states (including D.C.) with medical marijuana
laws require physicians directly or indirectly to authorize the use of
marijuana at their discretion, yet little is known about how medical
marijuana programs vary regarding adherence to basic principles of
medical practice and associated rates of enrollment. To explore this, we
analyzed marijuana programs according to seven components of
traditional medical care and pharmaceutical regulation. We then
examined enrollment rates, while controlling for potentially confounding
state characteristics. We found that fourteen of the twenty-four programs
were nonmedical and collectively enrolled 99.4 percent of participants
nationwide, with enrollment rates twenty times greater than programs
deemed to be “medicalized.” Policy makers implementing or amending
medical marijuana programs should consider the powerful relationship
between less regulation and greater enrollment. Researchers should
consider variations across programs when assessing programs’
population-level effects.
B
eginning with California in 1996,
twenty-three states and theDistrict
ofColumbiahave legalized thepos-
session and use of marijuana for
medical purposes. As of Octo-
ber 2014 more than one million Americans were
actively using marijuana under the aegis of such
laws.1 Although physicians have rarely been in-
volved in craftingmedicalmarijuana laws or pro-
gram regulations, all state programs task physi-
cianswith authorizingmarijuana use, directly or
indirectly, at their professional discretion. Peo-
ple who are eligible under state laws to partici-
pate in such programs and obtain a physician’s
authorization to do so are often required to reg-
ister in amedicalmarijuana programbefore they
can patronize dispensaries or grow a limited
amount of marijuana at home.2
State medical marijuana laws vary greatly in
their requirements and provisions.3 Early adopt-
er states, such as California, passed laws (often
via voter initiatives) that simply protected indi-
viduals who had received a physician’s authori-
zation for marijuana use from being prosecuted
for possession.More recently, states have begun
developing elaborate state-level agencies that
oversee the manufacturing, dispensing, and la-
beling of cannabis-derived productswithin high-
ly regulated programs.
Despite the great variation among state medi-
cal marijuana laws, published reports typically
categorize states as simply having or not having
medical marijuana laws.4 This approach over-
looks policy differences across states that may
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affect rates of participation and population-level
effects such as rates of use and heavy use, diver-
sion of medical marijuana to adolescents, drug
treatment admissions, and drugged driving.
However, previous research has not assessed
how medical marijuana laws vary across states
with respect to their adherence to traditional
standards of care in medicine.
To describe the variation among states, we
analyzed medical marijuana laws and program
regulations. We focused on the extent to which
they incorporated basic tenets of medical prac-
tice; Current GoodManufacturing Practices, the
main regulatory standard for ensuring pharma-
ceutical quality set by the Food andDrug Admin-
istration (FDA); and restrictions on controlled
substances.2,5
Marijuana’s anomalous status as anonconven-
tional alternative to pharmaceuticals prevents
easy comparisons between the use of marijuana
for medical purposes and traditional medical
care. Nevertheless, the extent to which medical
marijuana programs incorporate medical and
pharmaceutical regulations may affect which
people enroll in them (that is, people seeking
treatment for verifiable medical conditions ver-
sus recreational marijuana users).
We evaluated the strength of the association
between the medicalization of marijuana pro-
gramsandpopulation-based ratesof enrollment.
Finally, we assessed associationswith other state
characteristics thatmight contribute to program
enrollment, such as the number of physicians
per capita, the burden of terminal disease, medi-
cal marijuana costs, and baseline rates of recrea-
tional marijuana use.
Background
Medical marijuana is frequently promoted as
compassionate or palliative care for patients
with severe or terminal illnesses.4 Such patients
may use marijuana in an attempt to alleviate
symptoms such as chemotherapy-induced nau-
sea, AIDS-related cachexia (weakening or wast-
ing of the body), or intractable pain that has not
responded to conventional treatments.6 In addi-
tion, supporters ofmedicalmarijuana assert that
the use of marijuana (both the whole plant and
isolated compounds called cannabinoids) pro-
vides symptomatic relief for other debilitating
medical conditions such as amyotrophic lateral
sclerosis (ALS, or Lou Gehrig’s disease),7 multi-
ple sclerosis,8 and posttraumatic stress disorder9
and that it has few adverse effects.10
Unfortunately, few high-quality trials with
marijuana exist for most indications.5,11 This is
in large measure because of marijuana’s classifi-
cation as a Schedule I substance. Under the Con-
trolled Substances Act of 1970, Schedule I sub-
stances are deemed by the FDA and the Drug
Enforcement Administration as having no ther-
apeutic value and high potential for abuse.
Despite marijuana’s classification as a Sched-
ule I substance, a 1999 Institute of Medicine
(IOM) report concluded that cannabinoid
drugs—primarily delta-9-tetrahydrocannabinol
(THC)—had “potential therapeutic value” for
pain relief, control of nausea and vomiting,
and appetite stimulation.12(p3) The IOM limited
its recommendations to “short-term use of
smoked marijuana (less than six months) for
patients with debilitating symptoms.”12(p7)
More recently, two systematic reviews of clini-
cal trials concluded that high-quality evidence
for the therapeutic efficacy of cannabinoids is
limited to severe pain syndromes, neuropathic
pain, and spasticity such as that due to multiple
sclerosis.13,14 These reviews primarily evaluated
studies of existing FDA-approved medications
(instead of smoked whole-plant marijuana) that
are synthetic versions of THC, such as dronabi-
nol, nabilone, or nabiximols (a sublingual spray
containing THC and cannabidiol that has not yet
been approved for use in the United States).15
Critics charge that medical marijuana pro-
grams are actually Trojan horses for recreational
use and may cause more harm than proponents
are willing to acknowledge.16 Two cannabinoid-
based medications (dronabinol and nabilone)
have already been approved by the FDA, and
alternatives to smoking whole-plant marijuana
now exist, including vaporization with small
portable devices.17,18
Strong evidence has also emerged formarijua-
na-induced psychosis that can persist for days or
weeks beyond the initial period of intoxication,
especially formarijuana strainswith high-poten-
cy THC,19,20 and earlier onset of schizophrenia
among frequent marijuana users with familial
and genetic vulnerabilities.16,21,22 Physical depen-
dence, withdrawal,23 and clinical addiction affect
as many as 9 percent of adult and 16 percent of
adolescent frequent users.24,25
Of concern to policy makers, in many states
people receive authorizations for medical mari-
juana fromphysicianswhom they have seen for a
single visit, from whom they receive no diagno-
sis, and with whom they do not follow up.26,27
Initial studies have shown that the typical medi-
cal marijuana patient in these states is a young
male with a nonspecific indication of chronic or
severepain and ahistory of recreationalmarijua-
na use, instead of a patient receiving ongoing
medical care under a physician’s supervision
for a severe or terminal illness.28–30
Following the legalization of recreationalmar-
ijuana use in four states and the District of Co-
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lumbia, beginning in 2012, many commentators
viewed medical marijuana laws as stepping-
stones to inevitable legalization of marijuana
for recreational purposes.Yet the great variation
in medical marijuana laws complicates the poli-
tics underlying marijuana policy reform. Our
study addressed these issues by analyzing the
medical structure of marijuana programs, the
role of physicians, and the impact of regulation
on constraining versus expanding access to this
controversial drug.
Study Data And Methods
Sources Of Data And AssessmentWeanalyzed
legislation and program regulations from the
twenty-three states and the District of Columbia
with medical marijuana laws. Our analysis, in-
cluding year andmethod of initial passage (such
as voter initiative or legislative act),wasbasedon
laws and regulations publicly available through
the National Conference of State Legislatures
and state departments of health as of Decem-
ber 31, 2014, as documented in the online Ap-
pendix.31 We evaluated state programs according
to seven components common to medical prac-
tice and pharmaceutical regulation involving
controlled substances (Exhibit 1).
Two of the components, requiring a bona fide
doctor-patient relationship and using non-
smokedmedication, arewell-acceptedprinciples
of clinical practice. A state program was consid-
ered to require a bona fide doctor-patient rela-
tionship if the statute implementing the pro-
gram required the authorizing physician to
complete a full medical assessment, make a di-
agnosis, and manage ongoing care.32 Currently
no medication within the pharmacopeia is
smoked (because of the harms of smoking). Giv-
en alternatives to smoking (such as vaporizing
liquid concentrates), there is no clinical justifi-
cation for this route of administration.18
Exhibit 1




Physician must have bona fide clinical relationship with
patient, including completing full medical assessment,
making diagnosis, and managing ongoing care for
indicated condition.
The bedrock of clinical practice, the doctor-patient
relationship obligates the physician to monitor treatment
response and titrate dosing following diagnosis. These
skills are taught in graduate medical training and tested in
the United States Medical Licensing Examination
required for physician licensure (see Note 32 in text).
Manufacturing and
dispensing
State licensing required for marijuana manufacturing and
dispensing, which prohibits home cultivation or
procurement of marijuana outside of state-licensed
dispensaries.
Licensed manufacturing and dispensation ensure that
participants with valid prescriptions receive a consistent
product free of contaminants and minimize the risk of
diversion of marijuana to adolescents (see Note 33 in
text).
Testing and labeling Testing and labeling of marijuana cannabinoid profile
required. Of the more than 60 cannabinoids in marijuana,
dozens are thought to have therapeutic potential in
isolation or with “entourage” (combination) effects.
Identifying active ingredients, typically isolated molecular
entities, ensures patients of consistent content and
suggests their intended effects.a
Use of nonsmoked
medication
Marijuana use limited to nonsmoked products—that is, not
whole plants or home-cultivated product, but edibles or
concentrates for oral use or vaporization.
No evidence to date substantiates a therapeutic need for
smoked marijuana. Vaporizing and other routes of
administration have made smoking obsolete within
clinical practice (see Notes 17 and 26 in text).
30-day supply limits Supply of marijuana dispensed limited to 30-day amount
with no refills (unless authorized for up to 90 days,
consistent with standard prescribing practices).
The Controlled Substances Act of 1970 limits refills for
scheduled drugs such as methylphenidate (Schedule II),
hydrocodone (Schedule III), and benzodiazepines
(Schedule IV) (see Note 35 in text).
Prescription drug
monitoring program
Physician required to check patient’s profile in an online
statewide prescription drug monitoring program that
tracks prescription history.
States are increasingly implementing these programs and
requirements to help prevent illicit activity such as doctor
shopping and medication diversion (see Note 36 in text).
Physician training Physician must complete training to be certified as
marijuana-recommending provider.
High-risk medications such as buprenorphine, antibiotics for
multidrug-resistant organisms, and expensive
chemotherapies often can be prescribed only by
physicians with special training (see Note 37 in text).
SOURCE Authors’ analysis. NOTE The manufacturing and dispensing component is a prerequisite for the following two components: testing and labeling, and the use of
nonsmoked medication. aSee Note 34 in text and Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and
cannabidiol. Med Hypotheses. 2006;66(2):234–46.
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Two other components in Exhibit 1 are related
to the Current Good Manufacturing Practices
enforced by the FDA for pharmaceuticals.33
The principles of consistent and safe production
are reflected in programs’ requirements for
state-licensed manufacturing and dispensing
and uniform testing and labeling (of the
amounts and concentrations of individual can-
nabinoids) of marijuana products (irrespective
of the place of manufacture).5,15,33 Without uni-
form testing, consumers may receive marijuana
products that are mislabeled, contaminated, or
both.34
The following final three components in Ex-
hibit 1 were derived from restrictions on the use
of controlled substances by the Drug Enforce-
ment Administration and state law enforcement
agencies: a thirty-day limit on refills, linkage to
prescription drug monitoring programs, and
physician certification.35–37 States satisfied the
thirty-day refill criterion if they limited refills
to thirty-day periods, which is consistent with
current practice for controlled substances (such
as prescription stimulants or benzodiazepines).
Prescription drug monitoring programs that
track controlled substances are now operational
in virtually all states.38 Increasingly, physicians
are required to check these online databases of
patient prescription activity before prescribing
controlled substances.36 State programs satisfied
this criterion if they required authorizing physi-
cians to link to the state’s prescriptiondrugmon-
itoring program.
Finally, precedent exists for requiring special
training or certification for physicians who wish
to prescribe certain medications such as bupre-
norphine (categorized as a Schedule III con-
trolled substance, which means it has a risk of
abuse that could produce physical or psycholog-
ical dependence). Although there is disagree-
ment regarding the necessity for these restric-
tions on clinical practice, they reflect various
current federal and state regulations related to
controlled substances.
We categorized programs that met multiple
medical components (thus receiving a medical
orientation score greater than 1) as medicalized.
We categorized the other programs as nonmedi-
cal because there was minimal or no indication
that they adhered to basic tenets ofmedical prac-
tice or pharmaceutical regulation. We then as-
sessed rates of enrollment in medical marijuana
programswith respect to the program’s category
(medicalized or nonmedical), each of the seven
individual components, and state-level charac-
teristics.
Two of the authors—Arthur Robin Williams
and Mark Olfson, both physicians with experi-
ence in public health and social policy—indepen-
dently coded all documents containing state-lev-
el medical marijuana laws and current medical
marijuana program guidelines according to the
seven components listed above. Therewas a high
level of agreement between the reviewers, yield-
ing a kappa value of 0.95. Discordant codingwas
reconciled by consensus between Williams and
Olfson.
State Characteristics Chi-square tests and
t-tests were used to compare the background
characteristics of state programs—such as state
gross domestic product39 and census region40—
based on their level of medicalization (Ex-
hibit 2).
Covariates Of Enrollment Program enroll-
Exhibit 2
Characteristics of state medical marijuana programs passed as of October 1, 2014
Characteristic
Medicalized
programs (n = 10)
Nonmedical
programs (n = 14) p value
Created by legislative act 90.0% 28.6% 0.004
Mean years since passage of
medical marijuana law (SD) 2.7 (0.50) 13 (1.18) <0:0001









2008 state population densitya (SD) 1,454.1 (939.9) 146.45 (70.1) 0.11
State GDP (millions)b (SD) $393,429 ($113,390) $296,314 ($142,521) 0.62
Mean enrollment per 100,000 residentsc (SD) 58 (31.7) 1,030 (160.3) 0.002
SOURCE: Authors’ analysis. NOTES Most of the article’s analysis deals with the 19 programs (14 nonmedical and 5 medicalized) that
were in operation as of October 1, 2014. SD is standard deviation. aPopulation density data (people per square land mile) are derived
from US Census Bureau. Population estimates (see Note 40 in text). bGross domestic product (GDP) is expressed in 2013 seasonally
adjusted millions of dollars (see Note 39 in text). cEnrollment rates are derived from publicly available data sources for the five
medicalized programs and fourteen nonmedical programs that were in operation as of October 2014 (see Note 1 in text).
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ment rates were derived from publicly available
collated state figures for the nineteen medical
marijuana programs in operation as of Octo-
ber 2014.1 In addition to the total medical orien-
tation score, the following independent state-
level covariates were selected as factors that
might influence enrollment: the number of
physicians per capita, HIV prevalence, rate of
people in hospice care, program registration
costs, incremental or excise taxes, and rate of
recreational marijuana use (for further details
about the covariates, see the Appendix).31
The number of active physicians per 100,000
state residents in 2012 was derived from data
from the Association of American Medical Col-
leges.41 We evaluated HIV prevalence and rate of
people in hospice care as proxies for the burden
of severe or terminal disease by state, given that
most medical marijuana laws are passed explic-
itly for the care of these patient populations,
among others. Rates of HIV prevalence were ob-
tained from the 2011 HIV Surveillance Report.42
Rates of people in hospice care were estimated
with 2008 data from the Hospice Association of
America.43
Registration costs were obtained from pro-
gram websites and publicly available data that
reflected the lowest cost for enrolling in a state’s
marijuana program.44 Given variation in state
andmunicipal sales taxes,we restricted our anal-
ysis to incremental excise taxes for medical mar-
ijuana as a proxy for the additional out-of-pocket
expense for program enrollees.44 True out-of-
pocket expenses across states are difficult to de-
termine and have not been well characterized.45
States’ rates of recreationalmarijuanause (use
in the previousmonth by individuals ages twelve
and older) were estimated by aggregating 2012
and 2013 state-level public use reports from the
National Survey on Drug Use and Health.46 The
respondents to this survey are noninstitutional-
ized individuals living in the community or on
military baseswho collectively are representative
of a given state’s population. Higher state-level
prevalence of marijuana use has been positively
associated with the passage of medical marijua-
na laws but has not previously been evaluated in
association with program enrollment.47
Limitations Our study had several limita-
tions. First, it was limited by the number of med-
icalized programs with available enrollment fig-
ures, as full implementation of manufacturing
and dispensing practices often requires several
years.3 Because of the small number of medical-
ized programs in full operation (five), we were
unable to assess specific relationships between
less common components of medical marijuana
programs (such as requiring nonsmoked mari-
juanaor linkingmedicalmarijuanaprogrampar-
ticipation to prescription drug monitoring pro-
grams) and enrollment.
Second, we were also unable to assess the im-
pact of services provided by high-volume mari-
juana specialty clinics on rates of enrollment in
medical marijuana programs. Such specialty
clinics were founded following the passage of
medical marijuana laws. They solicit patients’
medical records (sometimes over the Internet),
conduct perfunctory patient evaluations, and
claim to have enrolled hundreds of thousands
of participants nationwide.48 They likely have a
disproportionate impact in states with marijua-
na programs that have little regulation. For in-
stance, one high-volume marijuana specialty
clinic system that operates in seven states (all
of which operate nonmedical programs) claims
to have enrolled over 250,000 patients in a fif-
teen-year period.27,48
Finally, although the seven components that
weassessed reflect commonclinical practice, it is
difficult to determine which components are
most relevant to the medical use of marijuana,
given its federal illegality and anomalous status
outside the standard purview of state and federal
regulation.
Study Results
Medical Orientation Considerable variation
existed across the twenty-three states and the
District of Columbia with medical marijuana
programs (for details, see the Appendix).31 The
mean total medicalization score was 1.96 (stan-
dard deviation: 2.15), with a range of 0 to 7 (on a
scale of 0 to 7). A bona fide doctor-patient rela-
tionship (Exhibit 1) was the most common com-
ponent, present in fifteen (62.5 percent) of
the programs. Only two programs (those in
Minnesota and New York) required nonsmoked
marijuana, and only three programs required
Stark differences in
enrollment may be
related to the process
by which medical
marijuana laws were
first passed in each
state.
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authorizing physicians to link to their state’s
prescription drug monitoring program (Con-
necticut, Massachusetts, and New York) or re-
quired physician certification through a state-
based licensing or training program (Maryland,
Massachusetts, and New York).
Programs in nine states and the District of
Columbia were considered medicalized because
they included more than one of the seven com-
ponents (mean score: 4.1; SD: 1.4). Nine of these
ten programs required exclusive state-licensed
manufacturing and dispensing, all of which re-
quired the testing and labeling of the cannabi-
noid profile of products. Six of the ten programs
implemented regulations reserved for controlled
substances.
The other fourteen programs were considered
nonmedical because they included only one or
none of the components (mean score: 0.43; SD:
0.51). Eight of these fourteen did not include any
of the components and thus had a score of 0. The
other six included only the component of a bona
fide doctor-patient relationship, giving each of
them a score of 1.
Eight of the fourteen nonmedical programs
had established state-licensed dispensaries as
an option for participants, and another program
(the one in California) allowed the use of dispen-
saries that were not regulated by the state.49 The
remaining five programs did not have dispensa-
ries, state-licensed or otherwise. As a result,
these fourteen nonmedical states allow either
home cultivation of marijuana or other forms
of procurement outside of state-licensed dispen-
saries.
Medicalized and nonmedical programs dif-
fered significantly with respect to route and year
of passage (Exhibit 2). Medicalized programs
were more likely than nonmedical ones to have
been created by legislative act (90.0 percent ver-
sus 28.6 percent) and to have been created more
recently.
Rate Of Enrollment Among the nineteen
programs in operation as of October 2014,
medicalized programs had approximately one-
twentieth the rate of enrollment of nonmedical
programs: 58 per 100,000 state residents (SD:
31.7) versus 1,030 (SD: 160.3), a significant dif-
ference (p ¼ 0:002) (data not shown). See Ex-
hibit 3 for further statisticalmodeling ofmedical
orientation and enrollment rates.
As a result, 99.4 percent of all participants
nationwide were in nonmedical programs. An
increase in the total medical orientation score
of one standard deviation was associated with a
180 percent reduction in the rate of enrollment
(p < 0:01) (seeAppendixC).31 Registration costs
were also inversely and significantly related to
enrollment rates, but with a smaller effect size:
An increase in the cost of one standard deviation
was associated with a 105 percent reduction in
enrollment (p < 0:01) (see Appendix C).31 For
further details, see the analyses in the Ap-
pendix.31
Except for program registration costs, enroll-
ment was not significantly related to any of the
independent state-level covariates listed above—
that is, the number of active physicians per cap-
ita, HIV prevalence, rate of people in hospice
care, incremental or excise taxes, or rate of rec-
reational marijuana use (for details, see the Ap-
pendix).31 In post hoc analyses,we found that the
strongest associations (inverse correlations)
were between enrollment rates and states’ re-
quiring state-licensed manufacturing and dis-
pensation as the only route of access to marijua-
na (p ¼ 0:002) and between enrollment rates
and states’ requiring uniform testing and label-
ing of products (p ¼ 0:002) (Exhibit 4).
Discussion
There was wide variation in the extent to which
the medical marijuana programs in the twenty-
three states and the District of Columbia embod-
ied principles of traditionalmedical practice and
pharmaceutical regulation. Fourteen of the
states used little regulation, and their programs
can be characterized as nonmedical. The other
nine states and the District of Columbia have
newer and more highly regulated programs that
can be characterized as medicalized.
Medicalizedprograms typically required state-
licensed manufacturing, dispensing, testing,
and labelingofmarijuana products.Half of these
programs also included restrictive elements for
Exhibit 3
Enrollment and medical orientation scores in state medical marijuana programs
SOURCE Authors’ analysis of information on 19 state medical marijuana programs in operation as of
October 27, 2014.
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controlled substances, suchas linkingmarijuana
program activity to prescription drug monitor-
ing programs or requiring physicians to com-
plete a specialized training course to be eligible
to authorize patient access to marijuana for
medical purposes. Among the nineteen state
programs in operation as of October 2014, the
medicalized programs had approximately one-
twentieth the rate of enrollment of the non-
medical programs.
Such stark differences in enrollment may be
related to the process by which medical marijua-
na laws were first passed in each state.We found
that early laws were mostly passed by voter ini-
tiative inwestern stateswith lowpopulationden-
sity, and the programs implemented under these
laws departed from a medical model. More re-
cent programs enacted by midwestern and
northeastern legislatures since 2009 are more
highly regulated and medicalized. These more
recent programs typically require years of work
at the state level between initial passage of a law
and full implementation of a state-licensed
manufacturing and dispensary system. They op-
erate in contrast to earlier programs that simply
permitted home cultivation of marijuana or pro-
vided state-level legal protections for marijuana
possession, sometimes without requiring mari-
juana users to formally register with the state.4
The effects of dispensaries on rates ofmarijua-
na use, heavy use, use of high-potency strains,
and changes in prices have received some atten-
tion in the policy literature.50,51 In general, epi-
demiological studies have beenmixed in linking
passage of medical marijuana laws with changes
in marijuana use.52,53 Mixed findings may stem
from variation across states with dispensaries
with respect to allowing othermeans ofmarijua-
na procurement. For instance, early-adopter
states allowed home cultivation long before
any state licensed a dispensary.2 Such variation
may confound the impact of dispensaries on
marijuana use. Lower rates ofmedicalmarijuana
use may occur when state-licensed dispensaries
are the onlymeans of access, which is the case in
nine of the ten medicalized programs and none
of the nonmedical programs. Additionally, the
mere presence of dispensaries may have less in-
fluence on marijuana use, compared to regula-
tions restricting who qualifies as dispensary
patrons.
Registration costs of medical marijuana pro-
grams were also significantly (negatively) asso-
ciated with enrollment rates. However, higher
registration costs (typically $50–$100 per year,
discounted for low-income state residents) may
be associated with lower enrollment rates if they
are secondary to the expense of state regulatory
agencies overseeingmanufacturinganddispens-
ing. For instance, registration costs of medical-
ized programs, which are presumably more ex-
pensive to operate, were approximately twice
those of nonmedical programs.
The time lag between initial passage of a law
and full implementation of a program may con-
tribute to the great discrepancy in enrollment
rates between medicalized and nonmedical pro-
grams.Yet time lags alone areunlikely to account
for all of the discrepancy. Rates of enrollment
were notably lower in all programs before
2009,50 given the great uncertainty at the time
related to the prospect of federal prosecution of
program staff members and participants.49 In
response to these concerns, the Department of
Justice released memos in 2009 and 2011 that
clarified federal intentions to refrain from inter-
fering with lawfully run programs at the state
level, which facilitated the consequent expan-
sion of enrollment.49,52
Conclusion
With the legalization of marijuana for recrea-
tional use by adults older than twenty-one in four
states and the District of Columbia, the country
has entered a new era of marijuana control poli-
cy. There has been a slow decades-long reversal
of marijuana prohibition—with physicians ini-
tially enlisted as gatekeepers to legal access to
marijuana for medical purposes—that may have
been a precursor to legalization of recreational
use in some states.
Our analysis revealed that virtually all of the
onemillion users of medical marijuana reside in
stateswith older nonmedical programs that have
minimal physician or state oversight. It is likely
not a coincidence that the states that legalized
recreational use ofmarijuana (Alaska, Colorado,
Oregon, and Washington) were states with non-
Exhibit 4
Enrollment in state medical marijuana programs and presence of four program components
SOURCE Authors’ analysis of information on 19 state medical marijuana programs in operation as of
October 27, 2014. NOTES The components are described in Exhibit 1. Each of the first three com-
ponents were included in nineteen programs; thirty-day supply limits were included in sixteen pro-
grams.
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medical programs first passed by voter initiative.
In effect, they have simply expanded the pool of
eligible users beyond the subset already using
marijuana for medical purposes. In contrast,
states with medicalized programs may be much
less likely to legalize recreational use in the fore-
seeable future.
There is a need for population-level research to
assess not only the presence of medical marijua-
na laws but also how program regulations affect
enrollment rates and who participates in the
programs. In particular, future research should
avoid simply classifying states as having versus
not having medical marijuana laws. As our find-
ings show, there is considerable variation in the
regulation of marijuana programs across states,
and this variation has a significant impact on
program enrollment. Additional studies are
needed to determine whether regulation also af-
fects who participates in the programs and
whether nonmedical programs disproportion-
ately attract recreational users.
In view of substantial differences in enroll-
ment rates betweenmedicalizedandnonmedical
programs, policy makers should evaluate for as-
sociations between specific program regulations
and unintended social costs—including rates of
illicitmarijuana use,medicalmarijuana diverted
to adolescents,marijuana-related emergency de-
partment visits and drug treatment admissions,
and drugged driving incidents—among partici-
pants in minimally regulated programs com-
pared to participants in highly regulated ones. ▪
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